PEG-MGF
A PEGylated version of Mechano Growth Factor engineered to extend the muscle-satellite-cell-activating action of the IGF-1 splice variant from minutes to days.
PEG-MGF is a synthetic, PEGylated form of Mechano Growth Factor (MGF), an alternatively spliced variant of IGF-1 (IGF-1Ec) that muscle produces locally in response to mechanical loading or damage. Its unique C-terminal E-domain (Ec) peptide activates satellite cells (muscle stem cells) rather than acting purely through classical IGF-1 receptor signaling. Attaching polyethylene glycol chains dramatically extends the plasma half-life from under 30 minutes for native MGF to roughly 24 hours (some sources cite 2-6 days), enabling systemic research dosing. It is researched primarily for muscle repair, satellite cell activation, and post-injury recovery, and has no regulatory approval or published human efficacy data.
Class
PEGylated IGF-1 splice variant (mechano growth factor E-domain peptide)
Half-life
~24 hours for the PEGylated form (some sources cite 2-6 days); native MGF is <30 minutes
Routes
Subcutaneous, Intramuscular, Intravenous
Category
Growth Hormone & Performance
Researched benefits
What it's studied for
Satellite cell activation and myonuclear accretion
The unique Ec-domain peptide activates Pax7+/MyoD+ muscle satellite cells, driving their proliferation and differentiation to add new myonuclei to existing muscle fibers. This is the primary researched mechanism and is supported by preclinical rodent and satellite-cell-biology work.
Accelerated muscle repair and recovery
Preclinical studies report enhanced recovery from exercise-induced muscle damage and injury, with increased muscle fiber cross-sectional area in rodent models. The mechanical-loading-responsive nature of native MGF makes it mechanistically relevant to exercise-induced adaptation.
Extended systemic activity vs native MGF
PEGylation extends the half-life from minutes to roughly a day or more, allowing systemic (rather than purely local, injection-site) research protocols that native MGF cannot practically support.
Anti-catabolic muscle signaling
Sources describe anti-catabolic signaling in muscle via activation of the PI3K/Akt pathway, consistent with the broader IGF-1 axis biology from which MGF is derived.
Cardioprotection in ischemia models
Preclinical ischemia models suggest cardioprotective effects attributed to interaction with FGFR signaling; this is an early, preclinical research signal rather than an established clinical effect.
Mechanism
How it works
MGF (Mechano Growth Factor) is a splice variant of IGF-1 (IGF-1Ec) expressed in skeletal muscle in response to mechanical stretch, loading, or damage. It carries a unique C-terminal E-domain extension (the Ec or MGF peptide) that distinguishes it from systemic IGF-1 and gives it a distinct biological role focused on local muscle repair.
Rather than acting solely through classical IGF-1 receptor signaling, the Ec-domain peptide activates satellite cells (Pax7+/MyoD+ muscle stem cells), promoting their proliferation and differentiation. This adds new myonuclei to existing muscle fibers (myonuclear accretion), which supports muscle repair and remodeling. Sources note the MGF receptor is described as a splice variant of IGF-1R, distinct from systemic IGF-1 signaling.
Native MGF is degraded within minutes, limiting it to local action. Chemically conjugating polyethylene glycol (PEG) chains improves aqueous stability and extends the in vivo half-life to roughly 24 hours (some sources cite 2-6 days), so the satellite-cell-activating action persists over a longer post-administration window and can be delivered systemically.
Because it operates through the IGF-1 axis, PEG-MGF is also associated with anti-catabolic PI3K/Akt signaling in muscle. Importantly, PEG-MGF has not been characterized in indexed peer-reviewed literature as a distinct chemical entity, so its pharmacokinetic and pharmacodynamic properties are extrapolated from research on the parent MGF compound rather than directly measured.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
Reconstitute the lyophilized powder with bacteriostatic water and store refrigerated after mixing. Vials are commonly supplied as 2 mg. Use a reconstitution calculator to convert vial size and BAC water volume into draw volume.
Standard (research)
- Dose
- ~200 mcg per administration
- Frequency
- Twice weekly
- Timing
- Community protocols often time doses around training or the post-exercise window
- Duration
- Not standardized; used in short research cycles
- Route
- Subcutaneous or intramuscular
This is the only quantitative regimen present in the sources (bodyhackguide.co). No validated tiered beginner/intermediate/advanced protocol is published, and dosing is not established by clinical data.
- No tiered beginner/intermediate/advanced protocol is published in the sources; a single ~200 mcg twice-weekly research regimen is the only quantitative guidance available.
- PEG-MGF is not approved for human consumption; research-use dosing in community protocols varies widely and is not backed by human trials.
- The extended half-life is the main practical rationale for systemic dosing versus native MGF, which is too short-acting for most applications.
- Because PEG chain length can vary by batch and vendor, effective peptide content per labeled milligram can be inconsistent; independent HPLC purity and mass-spectrometry identity confirmation are advised.
Combinations
Stacking & blends
TB-500 + PEG-MGF: Muscle Repair & Regeneration
Accelerate recovery from muscle injury and support lean tissue regeneration
Pairs TB-500's systemic anti-inflammatory and actin-binding tissue-repair properties with PEG-MGF's localized satellite cell activation, so a systemic recovery agent complements a local muscle-remodeling agent. Classified as a preclinical research pairing.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Active cancer or history of malignancy (theoretical mitogenic risk from IGF-axis activity)
- Uncontrolled or elevated IGF-1 levels
- Competitive athletes subject to anti-doping testing (WADA S2 prohibited)
Reported side effects in preclinical and community research use are mild and mostly local, and systemic effects are minimal due to the local-action profile. There is no controlled human safety data and long-term safety is unestablished. The PEG modification raises a theoretical concern about PEG-related immunogenicity with repeated administration, which has not been well-characterized for PEG-MGF specifically. IGF-axis compounds warrant caution in anyone with a history of malignancy.
FAQ
PEG-MGF — common questions
What is PEG-MGF?
PEG-MGF is a synthetic, PEGylated derivative of Mechano Growth Factor (MGF), an alternatively spliced variant of IGF-1 produced in muscle in response to mechanical loading. Its unique C-terminal E-domain peptide activates satellite cells (muscle stem cells). PEGylation extends its half-life from minutes to roughly a day or more, enabling systemic research dosing.
What's the difference between PEG-MGF and native MGF?
PEG-MGF has polyethylene glycol chains attached to native MGF, extending the half-life from minutes (native) to approximately 24 hours or, by some estimates, 2-6 days. This makes PEG-MGF practical for systemic research dosing, whereas native MGF is too short-acting for most applications.
Is PEG-MGF the same as IGF-1?
No. MGF is a splice variant of IGF-1 with a unique C-terminal extension expressed in muscle in response to mechanical loading. It binds a distinct receptor (an IGF-1R splice variant) and has different biological functions than systemic IGF-1. PEG-MGF is the PEGylated version of native MGF.
What is PEG-MGF researched for?
Primarily muscle repair, satellite cell activation, and post-injury recovery. Preclinical studies have shown satellite cell activation, increased muscle fiber cross-sectional area, and enhanced recovery from muscle damage in rodent models.
Does PEG-MGF have human clinical trial data?
No. Human clinical trial data specific to PEG-MGF is sparse, with no published Phase 2 or Phase 3 efficacy trials in muscle injury or sports recovery indications, and the compound does not appear in PubMed with characterized pharmacokinetic or pharmacodynamic properties.
Does PEG-MGF show up on a drug test?
Yes. MGF and IGF-1 analogs are on the WADA Prohibited List (Section S2, Peptide Hormones), so PEG-MGF is prohibited in tested sport.
Why does vendor verification matter for PEG-MGF?
PEG-MGF is a structurally complex peptide-PEG conjugate, and PEG chain length can vary by batch and vendor, adding molecular-weight variability. Some vendors sell native MGF mislabeled as PEG-MGF, so independent HPLC purity testing with mass-spectrometry identity confirmation is the key quality signal.
Is PEG-MGF legal?
PEG-MGF is generally legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption anywhere and has no regulatory approval.
